Commission clears JV by DocMorris and K-Mail Order; OK's Pfizer's pediatric Xalatan and Meda's Breakyl

22 October 2010

The European Commission has granted clearance under the EU Merger Regulation to the creation of a joint venture between DocMorris NV and K-Mail Order GmbH & Co KG. The joint venture will operate an internet and mail order pharmacy, with activities mainly in Germany.

DocMorris is a Dutch internet pharmacy with sales activities mainly in Germany. K-mail Order is a mail order and internet retailer for fashion, household goods and jewellery in Germany. The operation was examined under the simplified merger review procedure, the Commission said.

Pfizer announced yesterday that Xalatan 0.005% (latanoprost) has been approved by the European Commission for reduction of elevated intraocular pressure (IOP) in the treatment of pediatric patients with elevated intraocular pressure and paediatric glaucoma. Latanoprost is the first prostaglandin analogue to complete safety and efficacy trials in the pediatric population and be indicated for use in patients aged 18 years or younger in Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK